• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1共受体对CC趋化因子受体3的功能决定因素。细胞外区域和跨膜/细胞质区域的重要性。

Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions.

作者信息

Alkhatib G, Berger E A, Murphy P M, Pease J E

机构信息

Laboratory of Viral Diseases, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

J Biol Chem. 1997 Aug 15;272(33):20420-6. doi: 10.1074/jbc.272.33.20420.

DOI:10.1074/jbc.272.33.20420
PMID:9252350
Abstract

The chemokine receptors CXCR4, CCR2b, CCR3, and CCR5 are cell entry coreceptors for HIV-1. Using an HIV-1 envelope (Env)-dependent cell-cell fusion model of entry, we show that CCR3 can interact with Envs from certain macrophage (M)-tropic strains (which also use CCR5), T cell line (TCL)-tropic laboratory-adapted strains (which also use CXCR4), and a dual-tropic primary isolate (which also uses CCR2b, CCR5, and CXCR4). Paradoxically, CCR1 is the closest homologue to CCR3 (63% amino acid identity), but lacked HIV-1 coreceptor activity. These results confirm and extend previous reports. Replacing the N-terminal segment of CCR3 with that of CCR1 abolished activity of the resulting chimera for M-tropic and TCL-tropic Envs, but not for the dual-tropic Env. Replacing extracellular loop 2 of CCR3 with that of CCR1 abolished activity for TCL-tropic Envs, but not for M- and dual-tropic Envs. A chimera containing all four extracellular regions of CCR3 on a backbone of CCR1 lacked any activity. Env-CCR3 interactions were strongly inhibited by the major CCR3 ligand eotaxin, but weakly or not at all by other CCR3 ligands. With primary macrophages, eotaxin induced transient calcium flux and partially inhibited fusion with cells expressing M-tropic Envs. We conclude that specificity determinants for different Envs are located in shared and distinct extracellular regions of CCR3, the transmembrane/cytoplasmic domains make major contributions to coreceptor function, and CCR3 may be used by certain HIV-1 strains as a cell fusion factor on macrophages.

摘要

趋化因子受体CXCR4、CCR2b、CCR3和CCR5是HIV-1的细胞进入共受体。利用一种依赖HIV-1包膜(Env)的细胞间融合进入模型,我们发现CCR3可与某些巨噬细胞(M)嗜性毒株(其也利用CCR5)、T细胞系(TCL)嗜性的实验室适应毒株(其也利用CXCR4)以及一株双嗜性原代分离株(其也利用CCR2b、CCR5和CXCR4)的Env相互作用。矛盾的是,CCR1是与CCR3最接近的同源物(氨基酸同一性为63%),但缺乏HIV-1共受体活性。这些结果证实并扩展了先前的报道。用CCR1的N端片段替换CCR3的N端片段,使所得嵌合体对M嗜性和TCL嗜性Env失去活性,但对双嗜性Env则不然。用CCR1的胞外环2替换CCR3的胞外环2,使对TCL嗜性Env失去活性,但对M嗜性和双嗜性Env则不然。一个在CCR1骨架上含有CCR3所有四个胞外区域的嵌合体没有任何活性。主要的CCR3配体嗜酸性粒细胞趋化因子强烈抑制Env-CCR3相互作用,但其他CCR3配体则微弱抑制或完全不抑制。对于原代巨噬细胞,嗜酸性粒细胞趋化因子诱导瞬时钙流,并部分抑制与表达M嗜性Env的细胞的融合。我们得出结论,不同Env的特异性决定因素位于CCR3共享和不同的胞外区域,跨膜/胞质结构域对共受体功能起主要作用,并且某些HIV-1毒株可能将CCR3用作巨噬细胞上的细胞融合因子。

相似文献

1
Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions.HIV-1共受体对CC趋化因子受体3的功能决定因素。细胞外区域和跨膜/细胞质区域的重要性。
J Biol Chem. 1997 Aug 15;272(33):20420-6. doi: 10.1074/jbc.272.33.20420.
2
Human chemokine receptors CCR5, CCR3 and CCR2B share common polarity motif in the first extracellular loop with other human G-protein coupled receptors implications for HIV-1 coreceptor function.人类趋化因子受体CCR5、CCR3和CCR2B在第一个细胞外环中与其他人类G蛋白偶联受体共享共同的极性基序,这对HIV-1共受体功能具有重要意义。
Eur J Biochem. 1999 Aug;263(3):746-56. doi: 10.1046/j.1432-1327.1999.00553.x.
3
STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.STRL33,一种新型趋化因子受体样蛋白,作为巨噬细胞嗜性和T细胞系嗜性HIV-1的融合辅助因子发挥作用。
J Exp Med. 1997 Jun 2;185(11):2015-23. doi: 10.1084/jem.185.11.2015.
4
Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation.CCR5在人免疫缺陷病毒巨噬细胞嗜性毒株感染原代巨噬细胞和淋巴细胞中的作用:因CCR5基因缺失突变导致对患者来源毒株和原型毒株的抗性
J Virol. 1997 Apr;71(4):3219-27. doi: 10.1128/JVI.71.4.3219-3227.1997.
5
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.多种人类和猿猴免疫缺陷病毒对趋化因子受体、孤儿受体及疱疹病毒编码受体的利用情况。
J Virol. 1997 Dec;71(12):8999-9007. doi: 10.1128/JVI.71.12.8999-9007.1997.
6
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.CC趋化因子受体5:作为嗜巨噬细胞性HIV-1融合辅助因子的RANTES、巨噬细胞炎性蛋白-1α、巨噬细胞炎性蛋白-1β受体
Science. 1996 Jun 28;272(5270):1955-8. doi: 10.1126/science.272.5270.1955.
7
Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.通过与不同的CCR5和CXCR4结构域相互作用,HIV-1共受体使用情况的演变
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6426-31. doi: 10.1073/pnas.94.12.6426.
8
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.原发性人类免疫缺陷病毒1型分离株的共受体使用情况根据生物学表型而有所不同。
J Virol. 1997 Oct;71(10):7478-87. doi: 10.1128/JVI.71.10.7478-7487.1997.
9
Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity.决定HIV-1辅助因子特异性的β趋化因子受体CCR5和CCR2b中的区域。
Cell. 1996 Nov 1;87(3):437-46. doi: 10.1016/s0092-8674(00)81364-1.
10
CD4 receptor-dependent entry of human immunodeficiency virus type-1 env-pseudotypes into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor.人类免疫缺陷病毒1型包膜假型通过CD4受体依赖方式进入表达CCR5、CCR3和CXCR4的人肺泡巨噬细胞,这一过程优先由CCR5共受体介导。
Am J Respir Cell Mol Biol. 1999 May;20(5):864-71. doi: 10.1165/ajrcmb.20.5.3547.

引用本文的文献

1
Peripheral blood CD4CCR6 compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals.外周血 CD4CCR6 区室区分了 HIV-1 感染者或血清阳性的精英控制者与长期成功治疗的个体。
Commun Biol. 2022 Apr 13;5(1):357. doi: 10.1038/s42003-022-03315-x.
2
CXCR7/ACKR3-targeting ligands interfere with X7 HIV-1 and HIV-2 entry and replication in human host cells.靶向CXCR7/ACKR3的配体可干扰X7 HIV-1和HIV-2进入人类宿主细胞并在其中复制。
Heliyon. 2018 Mar 1;4(3):e00557. doi: 10.1016/j.heliyon.2018.e00557. eCollection 2018 Mar.
3
Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach.
CC 趋化因子受体(CCR5)的变构和变构结合位点,一种嵌合受体方法。
J Biol Chem. 2011 Oct 28;286(43):37543-54. doi: 10.1074/jbc.M111.243808. Epub 2011 Aug 30.
4
Ligand-based molecular design of 4-benzylpiperidinealkylureas and amides as CCR3 antagonists.基于配体的 4-苄基哌啶烷醇脲和酰胺类 CCR3 拮抗剂的分子设计。
J Mol Model. 2010 Apr;16(4):669-76. doi: 10.1007/s00894-009-0621-z. Epub 2009 Dec 4.
5
Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.通过替代共受体CCR3和FPRL1的病毒进入因人类免疫缺陷病毒1型亚型而异。
J Virol. 2009 Sep;83(17):8353-63. doi: 10.1128/JVI.00780-09. Epub 2009 Jun 24.
6
Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation.CCR3的小分子受体激动剂和拮抗剂为趋化因子受体激活机制提供了深入了解。
J Biol Chem. 2007 Sep 21;282(38):27935-43. doi: 10.1074/jbc.M703255200. Epub 2007 Jul 16.
7
Identifying epitopes of HIV-1 that induce protective antibodies.鉴定可诱导保护性抗体的HIV-1表位。
Nat Rev Immunol. 2004 Mar;4(3):199-210. doi: 10.1038/nri1307.
8
Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.鉴定出一组能够利用未转化的人脑和淋巴细胞上的替代共受体的1型人类免疫缺陷病毒(HIV-1)、HIV-2和猿猴免疫缺陷病毒毒株。
J Virol. 2003 Jun;77(11):6138-52. doi: 10.1128/jvi.77.11.6138-6152.2003.
9
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.人类免疫缺陷病毒蛋白酶的正负两方面:抑制剂的研发与其在艾滋病发病机制中的作用
Microbiol Mol Biol Rev. 2000 Dec;64(4):725-45. doi: 10.1128/MMBR.64.4.725-745.2000.
10
Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice.原发性R5型人类免疫缺陷病毒1型克隆在SCID-hu小鼠中的发病机制
J Virol. 2000 Apr;74(7):3205-16. doi: 10.1128/jvi.74.7.3205-3216.2000.